Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Peregrine Announces Participation at Upcoming Investor Conferences


Print article Print article
© Marketwire 2013
2013-02-26 22:02:28 -

TUSTIN, CA -- (Marketwire) -- 02/26/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that Steven W. King, president and chief executive officer, will participate at the following investor conferences:



  • 33rd Annual Cowen Health Care Conference
    Tuesday, March 5, 2013, at 10:40am Eastern Standard Time
    Marriott Copley Hotel Boston, Massachusetts


  • 25th Annual ROTH Conference
    Monday, March 18, 2013, at 2:00pm Pacific Daylight Time
    The Ritz Carlton Hotel Dana Point, California


  • Stifel Nicolaus & Company Biotechnology Investor Day
    Wednesday, March 20, 2013
    San Francisco, California






Peregrine's presentations at the Cowen and Roth Conferences will be webcast live and available for replay until April 12, 2013 and April 25, 2013, respectively at: http://ir.peregrineinc.com/events.cfm : ctt.marketwire.com/?release=990431&id=2669563&type=1& .. .



About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. ( www.avidbio.com : ctt.marketwire.com/?release=990431&id=2669566&type=1& .. ), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com : ctt.marketwire.com/?release=990431&id=2669569&type=1& .. .



Add to Digg : digg.com/submit?phase=2&url= www2.marketwire.com/mw/release_html_b1?release_id=990431 Bookmark with del.icio.us : del.icio.us/post?v=4&noui&jump=close&url= www2.marketwire.com/mw/release_html_b1?release_id=990431 Add to Newsvine : www.newsvine.com/_tools/seed&save?u= www2.marketwire.com/mw/release_html_b1?release_id=990431




Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com : docid: 13990431.nitf -->



Press Information:




Contact Person:


Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser